TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05308862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care process for assessements of risks
Description: Intervention aiming to reduce the risk of pressure ulcers, malnutrition, poor oral health and falls among older persons in nursing homes, workshops will be conducted in collaboration with nurse aides, registered nurses and managers. Cluster randomization is going to take place via a computerized program prior to the workshops meaning that only those nurse aides, registered nurses and managers working in nursing homes allocated to the intervention group are going to develop an intervention together with the research group and then test it .
Study: NCT06042647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.01% Halobetasol
Description: Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.045% Tazarotene
Description: Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% Clobetasol Propionate
Description: Drug to be applied to designated psoriatic plaque at bedtime.
Study: NCT05401149

Intervention type: DRUG
Intervention: rt-PA
Description: Recombinant Tissue Plasminogen Activator
Study: NCT05282316

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EVOO polyphenols enriched
Description: Addition of 40 ml daily of healthy polyphenols enriched EVOO to mediterranean diet for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EVOO standard
Description: Addition of 40 ml daily of standard EVOO to mediterranean diet for 6 months
Study: NCT06182527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free Style Libre Pro IQ
Description: Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded.
Study: NCT05039047

Intervention type: OTHER
Intervention: Standard stroke acute care and rehabilitation
Description: According to Swiss national guidelines and local protocols
Study: NCT04148443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoxygenation
Description: participants will receive 3 minutes of preoxygenation before intubation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoxygenation (longer)
Description: participants will receive 5 minutes of preoxygenation before intubation
Study: NCT05637021

Intervention type: OTHER
Intervention: Carbon dioxide insufflated during colonoscopy
Description: Carbon dioxide is insufflated to dilate the bowel lumen during colonoscopy.Record the amount of gas insufflated during colonoscopy.
Study: NCT05930327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfer (High-Value)
Description: Monthly, Unconditional Cash Transfer ($325) for 4-months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unconditional Cash Transfer (Low-Value)
Description: Monthly, Unconditional Cash Transfer ($25) for 4-months
Study: NCT05949762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venetoclax in Combination With Azacitidine and HA Regimen
Description: Patients diagnosed with primary AML based on morphology, immunophenotyping, and history and meeting the inclusion exclusion criteria were induced with Venetoclax in combination with Azacitidine and HA regimen.~Details for:~Venetoclax 200mg d1-10 Azacitidine 100mg/d (or 50-75mg/m2/d), d2-7 Hautriacontin 2mg/m2/d, d3-7 Cytarabine 100mg/m2/d, d3-8 (infusion 24h)
Study: NCT05767944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local anaesthesia infiltration
Description: Infiltration of 150 mg of lidocaine solution per ray at site of surgical incision for flexor tendon repair in the palm, the 2 proximal \& distal phalanges

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block
Description: ultrasound-guided infiltration of local aesthetics around brachial plexus trunks \& divisions
Study: NCT05106231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PICC Program
Description: Participants will attend the PICC program which consists of 4 sessions that involve Visualization in Participatory Programmes (VIPP) and quizzes to evaluate retention in diabetes knowledge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control arm received four sessions one-on-one education program by a pharmacist. It is a Malaysian national education pharmacy-led program to instil knowledge and inculcate medication adherence.
Study: NCT04287452

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dog Therapy
Description: Exposure to certified therapy dogs and their handler.
Study: NCT05036915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pacifier randomly
Description: Common Action Steps:~1. Legal representatives of newborns are informed about the study purpose, participants read and sign the informed consent form so their consent is obtained.~2. Inclusion and exclusion criteria are evaluated.~3. Study group is determined in line with the randomization order of the newborn to be included in the study.~4. First part of the patient information and follow-up form is completed.~5. Feeding content, amount and method are determined by the physician.~Action Steps of the Control Group:~\* Pacifier is randomly given to the infant for 30 min independent from feeding during the day.~1. Common procedure steps are applied.~2. Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~3. Second part of the patient information and follow-up form is completed daily.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pacifier other
Description: Procedure Steps of the Experimental Group:~* Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.~  1. Common procedure steps are applied.~ 2. Pacifier is given for 5 min before each feeding.~ 3. Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~ 4. Second part of the patient information and follow-up form is completed daily.
Study: NCT05664750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNM002
Description: Dosage Form: Injection, solution~Route of administration: IM gluteal injection
Study: NCT05570682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCI
Description: General anesthesia will be induced with a TCI pump

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual induction
Description: General anestehsia will be induced and maintained using a pro kilo regimen.
Study: NCT04740515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacists involved PPMTM
Description: This was an open labelled randomised study. Preterm Infants With iron supplementation were recruited and arbitrarily divided into the intervention group (usual care plus PPMTM) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
Study: NCT00518024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Bilateral Theta Burst Stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Bilateral Theta Burst Stimulation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Bilateral Theta Burst Stimulation
Study: NCT05004324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL
Description: the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL
Description: the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
Study: NCT05585424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AOT intervention
Description: The treatment will last 4 weeks, with an intensity of 3 sessions per week. During the sessions the MCI patient will observe his MCI partner and perform a programme of upper limb motor activities. At the same time the mild patient imitates the movement performed by the physiotherapist, all based on the AOT.~The activities will be based on items of the FUGL-MEYER scale. The sessions will last between 15 and 20 minutes and will be held three days a week. The intervention will last 5 weeks, with an initial assessment, 11 intervention sessions and a final assessment.
Study: NCT05234164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXIST 6F NiTi Stent System FLEX
Description: Subjects requiring treatment of the P1 segment of the proximal popliteal artery will be treated with the Exist 6F NiTi Stent FLEX type. Subjects requiring treatment of the SFA will undergo an additional calcification review based on the Fanelli classification. Subjects graded with Fanelli 1 or 2 will be treated with the Exist 6F NiTi Stent FLEX type.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXIST 6F NiTi Stent System PULL
Description: Subjects requiring treatment of the SFA will undergo a calcification review based on the Fanelli classification. Subjects graded with Fanelli grade 3 and 4 will be treated with the Exist 6F NiTi Stent PULL type.
Study: NCT04867564

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Traditional echocardiography and speckle tracking echocardiography (STE) before and 1, 6, and 12 months after RT
Study: NCT05548595

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational
Description: 2 tablets are taken with water around the same time every day, ideally after a meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets are taken with water around the same time every day, ideally after a meal
Study: NCT05623150

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver biopsy
Description: Liver biopsy planned as part of routine care. Clinical-biological characterisation with bio collections.
Study: NCT05247151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin nasal spray in a positive social setting.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray in a positive social setting.
Study: NCT06288984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS
Description: The magnetic stimulation coil was tangent to the scalp and kept parallel for 10 minutes a day, 5 days a week for 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: The magnetic stimulation coil was tangent to the scalp and kept perpendicular for 10 minutes a day, 5 days a week for 4 weeks
Study: NCT04728243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHO QualityRights e-training
Description: The WHO QualityRights online training aims to increase knowledge about the rights of people with psychosocial disabilities and change negative attitudes towards these persons and their role as rights holders. Furthermore, the training provides mental health professionals with the skills necessary to support people with psychosocial disabilities to advocate for their rights. The WHO QualityRights online training includes five core modules: 1) Human rights; 2) Mental health, disability, and human rights; 3) The right to health and recovery; 4) Legal capacity and the right to decide; 5) Free from coercion, violence, and abuse. Each module is composed of presentations, videos, interactive exercises, and forum discussions involving all participants. In the online training forum discussions, particular attention will be given to issues relevant to the Ghanaian context.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WHO COVID-19 online training
Description: The WHO novel coronavirus 2019 online training series provides a general introduction to COVID-19 and similar respiratory infections and information on what facilities and professionals should be doing to prevent and respond to COVID-19 cases. The training is similar in length to the WHO QualityRights training (13 h 15 min vs. 19 hours) and is intended for health professionals and other stakeholders.
Study: NCT05427786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Administer 8cc or more of the prescribed drug according to randomization into the coronary artery before starting balloon therapy. The stent treatment method follows the standard treatment method.
Study: NCT05897099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Tele-harm Reduction
Description: Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Off-site Linkage to HIV Prevention
Description: The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
Study: NCT04709536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI306
Description: Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
Study: NCT05710068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Microneedle
Description: Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination cream
Description: 5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination cream
Description: 5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
Study: NCT05868083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNC-109 CAR-T Cells
Description: SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
Study: NCT05811338

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement
Description: The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement
Description: The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project 2, Phase 2: Intelligent Adaptive System
Description: An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project 2, Phase 2: Intelligent Adaptive System
Description: An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project 3, Phase 3: Intelligent Decision Support Tool
Description: An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project 3, Phase 3: Intelligent Decision Support Tool
Description: An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
Study: NCT05780645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050 MR Prototype Tablet
Description: Participants will receive various doses of the MR Prototype Tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050 Immediate Release (IR) Tablet
Description: Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050 Immediate Release (IR) Tablet
Description: Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050 MR Prototype Mini-Tablet
Description: Participants will receive various doses of the MR Prototype Mini-Tablet orally.
Study: NCT06534567

Intervention type: OTHER
Intervention: Mediterranean Diet
Description: Mediterranean diet adherence

Intervention type: OTHER
Intervention: Mediterranean Diet
Description: Mediterranean diet adherence

Intervention type: OTHER
Intervention: Physical activity
Description: Physical activity level

Intervention type: OTHER
Intervention: Physical activity
Description: Physical activity level
Study: NCT05664750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human tetanus immunoglobulin (HTIG)
Description: Dosage Form: Injection, solution~Route of administration: IM gluteal injection
Study: NCT05402761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-guided BBTi group
Description: On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi. In the end of week 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-delivered BBTi group
Description: They will use the app in conjunction with the standard BBTi procedures provided by the app, such as stimulus control, sleep restriction and audio-guided relaxation techniques (suggest to use before bedtime).
Study: NCT05313620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 5 MG/day per clinical practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab Adalimumab y Golimumab
Description: Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.
Study: NCT05058859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes
Study: NCT04946656

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sphenopalatine ganglion block
Description: The sphenopalatine ganglion will be blocked with bupivacaine for this study
Study: NCT06361082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Description: ACL reconstruction
Study: NCT04855708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual visit
Description: Patients randomized to this group will have a virtual 2-week post-operative visit
Study: NCT06313762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet
Description: They will experience in first person the two and a half minute graphic adventure, called Leia\&amp;amp;amp;amp;#39;s World, during the administration of the vaccines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Distractors
Description: The control group participants will receive traditional distractors, such as being held by the parent or guardian who accompanies them to the appointment, receiving stickers at the end of the appointment, or receiving rewards that the parent or guardian has prepared from home, during the administration of the vaccines.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple Viral + Varicella Vaccine at 3 years of age
Description: Administration of vaccines in 3-year-old children, as appropriate according to the vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Triple Viral + Varicella Vaccine at 3 years of age
Description: Administration of vaccines in 3-year-old children, as appropriate according to the vaccination schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age.
Description: Administration of vaccines in 6-year-old children, as appropriate according to the vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age.
Description: Administration of vaccines in 6-year-old children, as appropriate according to the vaccination schedule.
Study: NCT05268666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBI-802
Description: LSD1/HDAC6 inhibitor